Want to see HK:1167 full AI Analyst Report?
1167 Stock Chart & Stats
HK$8.06
HK$0.04(3.17%)
At close: 4:00 PM EST
HK$8.06
HK$0.04(3.17%)
Day’s Range― - ―
52-Week RangeHK$3.98 - HK$10.23
Previous CloseN/A
Volume546.60K
Average Volume (3M)2.82M
Market Cap
HK$4.70B
Enterprise ValueHK$2.15K
Total Cash (Recent Filing)HK$1.10B
Total Debt (Recent Filing)HK$165.24M
Price to Earnings (P/E)7.8
Beta0.95
Next Earnings
Mar 24, 2027EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding791,755,070
10 Day Avg. Volume1,253,384
30 Day Avg. Volume2,822,551
Financial Highlights & Ratios
PEG Ratio3.18
Price to Book (P/B)5.75
Price to Sales (P/S)84.99
P/FCF Ratio-23.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.34Price Target Upside28.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$723.51M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageRelatively low leverage gives Jacobio greater balance-sheet flexibility than a heavily indebted biotech, allowing more room to fund research, clinical programs, or operating needs. This cushion may help the company manage volatility while it works toward pipeline monetization.
Targeted Oncology PipelineA focused oncology and precision-medicine strategy can support differentiated drug development around defined molecular pathways. If clinical candidates demonstrate value, this platform may create partnering or licensing opportunities and provide multiple routes to future pipeline monetization.
Potentially Strong Gross MarginsStrong gross margins in recent periods indicate that certain revenue streams can carry attractive economics before research and operating costs. Although profitability has not yet followed, this provides a potentially favorable foundation if development assets generate larger or more recurring revenue.
Bears Say
Sharp Revenue ContractionA roughly 74% year-on-year revenue decline signals substantial volatility in the current monetization model. For a clinical-stage company relying heavily on partnerships and milestones, such swings can reduce visibility, complicate planning, and make future funding dependent on uncertain transaction timing.
Persistent UnprofitabilityRecurring operating and net losses show that current revenue does not cover the cost of advancing the business. Continued negative margins may persist while clinical programs require investment, limiting internal funding capacity and increasing the importance of successful development or partnering outcomes.
Sustained Cash BurnNegative operating and free cash flow across most recent years indicates that Jacobio is not yet self-funding its activities. Higher 2025 cash burn increases sensitivity to external capital or remaining balance-sheet resources and could constrain the pace of pipeline development if funding conditions tighten.
Jacobio Pharmaceuticals Group Co., Ltd. News
1167 FAQ
What was Jacobio Pharmaceuticals Group Co., Ltd.’s price range in the past 12 months?
Jacobio Pharmaceuticals Group Co., Ltd. lowest stock price was HK$3.98 and its highest was HK$10.23 in the past 12 months.
What is Jacobio Pharmaceuticals Group Co., Ltd.’s market cap?
Jacobio Pharmaceuticals Group Co., Ltd.’s market cap is HK$4.70B.
When is Jacobio Pharmaceuticals Group Co., Ltd.’s upcoming earnings report date?
Jacobio Pharmaceuticals Group Co., Ltd.’s upcoming earnings report date is Mar 24, 2027 which is in 177 days.
How were Jacobio Pharmaceuticals Group Co., Ltd.’s earnings last quarter?
Jacobio Pharmaceuticals Group Co., Ltd. released its earnings results on Aug 24, 2026. The company reported HK$0.901 earnings per share for the quarter, beating the consensus estimate of HK$0.012 by HK$0.889.
Is Jacobio Pharmaceuticals Group Co., Ltd. overvalued?
According to Wall Street analysts Jacobio Pharmaceuticals Group Co., Ltd.’s price is currently Undervalued.
Does Jacobio Pharmaceuticals Group Co., Ltd. pay dividends?
Jacobio Pharmaceuticals Group Co., Ltd. does not currently pay dividends.
What is Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate?
Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate is 0.01.
How many shares outstanding does Jacobio Pharmaceuticals Group Co., Ltd. have?
Jacobio Pharmaceuticals Group Co., Ltd. has 791,755,070 shares outstanding.
What happened to Jacobio Pharmaceuticals Group Co., Ltd.’s price movement after its last earnings report?
Jacobio Pharmaceuticals Group Co., Ltd. reported an EPS of HK$0.901 in its last earnings report, beating expectations of HK$0.012. Following the earnings report the stock price went down -1.994%.
Which hedge fund is a major shareholder of Jacobio Pharmaceuticals Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1167
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jacobio Pharmaceuticals Group Co., Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
52.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
1167 Stock 12 Month Forecast
Average Price Target
HK$10.34
▲(28.29% Upside)
Technical Analysis
Antengene Corporation Limited
―
Genor Biopharma Holdings Limited
―
Alphamab Oncology
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―